BioSpace News Archive

Breast Cancer patients are 60 percent more likely to die of cancer after surviving a heart attack, a new study finds.

Sirius Automation Group, a market leader in benchtop Sample Preparation and Manipulation Laboratory Automation Workstations, is proud to announce their collaboration with Cerulean of Milton Keynes, United Kingdom.

uLab Systems, the creator of uDesign - the treatment planning software designed for orthodontists - is expanding its product offering to include aligner manufacturing

Major League Lacrosse (MLL) today announced a partnership with Biodesix, Inc., whereby Biodesix will be the exclusive provider of COVID-19 testing for the upcoming 2020 MLL season.

Professor Cheng Chao-Min of the Institute of Biomedical Engineering at National Tsing Hua University has recently developed a new covid-19 rapid test kit which allows the physician to provide timely treatment to high-risk patients, thereby making more efficient use of such critical equipment as respirators.

A drug used to treat systemic lupus erythematosus (SLE) significantly reduces the incidence of a rare and sometimes fatal heart condition in newborn babies, a new study from NYU Grossman School of Medicine researchers shows.

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that Dr. Jack Zamora M.D. has joined its executive team as its Chief Medical Advisor.

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced the record date for the Company’s planned rights offering

Genentech, a member of the Roche Group, announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® to Avastin®, paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival for the front-line treatment of women with newly-diagnosed advanced-stage ovarian cancer.

The global medical gas equipment market is prognosticated to be significantly advantaged by the augmenting prevalence of respiratory ailments strengthening the rise of point-of-care diagnostics.